Zhi-Kai Zheng Jiong-Liang Wang Wen-Xuan Li Tian-Qing Wu Min-Shan Chen Zhong-Guo Zhou
10.3389/fpubh.2022.917679
Front Public Health
2022 Jun 16;10:917679.
anti-programmed cell death protein-1 immune checkpoint inhibitors immune-related adverse events intrahepatic cholangiocarcinoma type 1 diabetes
CC BY
https://pubmed.ncbi.nlm.nih.gov/35784237/
Bile Duct Neoplasms / complications Bile Duct Neoplasms / drug therapy Cholangiocarcinoma / complications Cholangiocarcinoma / drug therapy Diabetes Mellitus, Type 1 / complications Diabetes Mellitus, Type 1 / diagnosis Insulins / adverse effects Ketosis / complications
Bile Duct Neoplasms / complications Bile Duct Neoplasms / drug therapy Cholangiocarcinoma / complications Cholangiocarcinoma / drug therapy Diabetes Mellitus, Type 1 / complications Diabetes Mellitus, Type 1 / diagnosis Insulins / adverse effects Ketosis / complications Case Reports Review Research Support, Non-U.S. Gov't Bile Ducts, Intrahepatic Cell Death Female Humans Middle Aged Insulins
PMC9243496
35784237
Anti-programmed Cell Death Protein-1 Therapy in Intrahepatic Cholangiocarcinoma Induced Type 1 Diabetes: A Case Report and Literature Review
2022